Scilex Holding

0.19
-0.01 (-3.11%)
At close: Apr 14, 2025, 3:59 PM
0.19
0.80%
After-hours: Apr 14, 2025, 06:40 PM EDT
-3.11%
Bid 0.17
Market Cap 45.48M
Revenue (ttm) 56.59M
Net Income (ttm) -72.81M
EPS (ttm) -0.61
PE Ratio (ttm) -0.31
Forward PE -1.48
Analyst Buy
Ask 0.19
Volume 1,867,131
Avg. Volume (20D) 1,454,327
Open 0.21
Previous Close 0.20
Day's Range 0.17 - 0.21
52-Week Range 0.17 - 2.30
Beta 1.05

About SCLX

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural i...

Sector Healthcare
IPO Date Mar 5, 2021
Employees 115
Stock Exchange NASDAQ
Ticker Symbol SCLX
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for SCLX stock is "Buy." The 12-month stock price forecast is $13, which is an increase of 6855.59% from the latest price.

Stock Forecasts
4 days ago
-21.53%
Scilex Holding shares are trading lower after the ... Unlock content with Pro Subscription
1 week ago
+25.26%
Scilex Holding shares are trading higher. D. Boral Capital maintained a Buy rating on the stock.